The importance of residual endogenous beta-cell preservation in type 1 diabetes

British Journal of Diabetes and Vascular Disease

Volumn 9, Issue 6, 2009, Pages 248-253

  Ali, Mohammad Alhadj ^a   Dayan, Colin M ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Beta cell preservation; C peptide; Immunotherapy; Type 1 diabetes

Indexed keywords

C PEPTIDE; CD3 ANTIBODY; HEMOGLOBIN A1C; INSULIN; PREPROINSULIN; PROINSULIN;

AUTOIMMUNITY; BODY MASS; CELL FUNCTION; DIABETIC KETOACIDOSIS; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; METABOLIC REGULATION; PANCREAS ISLET BETA CELL; PEPTIDE SYNTHESIS; PRESERVATION; REVIEW;

EID: 74549155004     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651409351881     Document Type: Review

References (46)

1. D iagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32(suppl 1):S62-7.
2. Achenbach P, Warncke K, Reiter J et al. Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody- positive relatives. Diabetologia 2006;49:2969-2976
3. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-2608 (Pubitemid 41007846)
4. Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 2006;49:261-270
5. Faber OK, Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 1977;26: 605-610
6. D iabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009;169:1307-1316
7. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271-286
8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
9. Sjoberg S, Gunnarsson R, Gjötterberg M et al. Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987;30:208-213
10. Madsbad S, Alberti KG, Binder C et al. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J 1979;2:1257-1259
11. Fukuda M, Tanaka A, Tahara Y et al. Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 1988;37:81-88
12. Martin S, Pawlowski B, Greulich B et al. Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care 1992;15:66-74.
13. Marques RG, Fontaine MJ, Rogers J. C-peptide: much more than a byproduct of insulin biosynthesis. Pancreas 2004;29:231-238
14. Kruszynska YT, Home PD, Hanning I, Alberti KG. Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia 1987;30:16-21.
15. Williams AJ, Chau W, Callaway MP, Dayan CM. Magnetic resonance imaging: a reliable method for measuring pancreatic volume in type 1 diabetes. Diabet Med 2007;24:35-40.
16. Teuscher AU, Kendall DM, Smets YF et al. Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 1998;47:324-330
17. Sosenko JM, Palmer JP, Greenbaum CJ et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643-649
18. Greenbaum CJ, Mandrup-Poulsen T, McGee PF et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of betacell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971
19. Steele C, Hagopian WA, Gitelman D et al. Insulin secretion in type 1 diabetes. Diabetes 2004;53:426-33.
20. Greenbaum CJ, Anderson AM, Dolan LM et al. Preservation of betacell function in autoantibody positive youth with diabetes. Diabetes Care 2009;32:1839-1844
21. Scholin A, Björklund L, Borg H et al. Islet antibodies and remaining beta-cell function 8 years after diagnosis of diabetes in young adults: a prospective follow-up of the nationwide Diabetes Incidence Study in Sweden. J Intern Med 2004;255:384-391
22. Palmer JP, Fleming GA, Greenbaum CJ et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264
23. Karjalainen J, Salmela P, Ilonen J et al. A comparison of childhood and adult type I diabetes mellitus. N Engl J Med 1989;320:881-886
24. Bonfanti R, Bazzigaluppi E, Calori G et al. Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus. Diabet Med 1998; 15:844-850
25. Peig M, Gomis R, Ercilla G et al. Correlation between residual beta-cell function and islet cell antibodies in newly diagnosed type I diabetes. Follow-up study. Diabetes 1989;38:1396-1401
26. Sochett EB, Daneman D, Clarson C, Ehrlich RM. Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children. Diabetologia 1987;30:453-459
27. Torn C, Landin-Olsson M, Lernmark A et al. Prognostic factors for the course of beta-cell function in autoimmune diabetes. J Clin Endocrinol Metab 2000;85:4619-4623
28. Palmer JP. C-peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev 2009;25:325-328
29. The DCCT Research Group. Effect of intensive therapy on residual β-cell function in patients with type I diabetes in the Diabetes Control and Complications Trial. Ann Intern Med 1998;128:517-523
30. Montanya EM, Fernandez-Castaner M, Soler J. Improved metabolic control preserved beta-cell function two years after diagnosis of insulin- dependent diabetes mellitus. Diabetes Metab 1997;23:314-319
31. Fourlanos S, Narendran P, Byrnes GB et al. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004;47:1661-1667
32. Bingley PJ, Mahon JL, Gale EA. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008;31:146-150
33. Panero F, Novelli G, Zucco C et al. Fasting plasma C-peptide and microand macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 2009;32:301-305
34. Ryan EA, Paty BW, Senior PA et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005;54:2060-2069
35. Toso C, Shapiro AM, Bowker S et al. Quality of life after islet transplant: impact of the number of islet infusions and metabolic outcome. Transplantation 2007;84:664-666
36. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836
37. Madsbad S, Lauritzen E, Faber OK, Binder C. The effect of residual beta-cell function on the development of diabetic retinopathy. Diabet Med 1986;3:42-45
38. Ludvigsson J, Faresjö M, Hjorth M et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359: 909-920
39. Wahren J, Ekberg K, Jornvall H. C-peptide is a bioactive peptide. Diabetologia 2007;50:503-509
40. J ohansson BL, Borg K, Fernqvist-Forbes E et al. C-peptide improves autonomic nerve function in IDDM patients. Diabetologia 1996;39: 687-695
41. Sima AA, Zhang W, Sugimoto K et al. C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat. Diabetologia 2001;44:889-897
42. Samnegard B, Jacobson SH, Jaremko G et al. Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney Int 2001;60:1258-1265
43. J ohansson BL, Borg K, Fernqvist-Forbes E et al. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 2000;17:181-189
44. Ekberg K, Brismar T, Johansson BL et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007;30:71-76
45. Luzi L, Zerbini G, Caumo A. C-peptide: a redundant relative of insulin? Diabetologia 2007;50:500-502
46. Fleming, A., What will it take to get therapies approved for type 1 diabetes? Ann N Y Acad Sci 2008;1150:25-31.